Ribometrix Announces Lead Program Target and Presentation of Preclinical Data at the International C

-- Disclosure of eIF4E, a regulator of oncoprotein translation, as target of most advanced program ---- Data demonstrate strong in vivo anti-tumor effects of orally bioavailable small molecules; IND enabling studies planned ---- Additional data to be presented at San Antonio Breast Cancer Symposium in early December...

Related Keywords

Philadelphia , Pennsylvania , United States , North Carolina , San Antonio , Texas , Allison Gleason , Brafi Meki , Michael Solomon , Matthew Friedersdorf , Genentech , Vertex Pharmaceuticals , Roche Group , Society For Melanoma Research , International Congress , San Antonio Breast Cancer Symposium , Melanoma Research , Chief Executive Officer ,